“Nothing stops a drug from working like not taking it, making patient adherence one of the most important factors to consider when designing a clinical trial.”
– Bernard Vrijens, Scientific Lead, AARDEX® Group
Poor patient adherence is a problem that has gone “unsolved” for decades. But combining smart pill bottle technology with individualized feedback can drive the adherence that proves the investigational product efficacy and underwrites approvals.
In this case study, we set out the crucial role of medicine-taking behavior in clinical research and explain how using AARDEX® Group’s Smart Pill Bottle, MEMS® Caps, in a study of Gilead’s Truvada helped inform the FDA’s recommended approach to tackling poor patient adherence in clinical trials, as set out in its Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products.
